M&A Deal Summary |
|
|---|---|
| Date | 2024-10-16 |
| Target | Rebound |
| Sector | Life Science |
| Buyer(s) | Celularity |
| Sellers(s) | Sequence Life Science |
| Deal Type | Divestiture |
SEARCH BY
Celularity, Inc. is a biotechnology innovation leader, harnessing the power of placental-derived cell populations to deliver transformative, allogeneic off-the-shelf immunotherapies and cell therapies for cancer and other serious diseases. Celularity is based in Warren, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2024 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-08-31 |
CariCord
Irvine, California, United States CariCord, Inc. is a provider of an all laboratory processing and repository needs, and also provides CariCord a direct association with the adjacent facilities, including University of Colorado Anschutz Medical Campus, The Veterans Hospital and Children’s Hospital Colorado. CariCord was founded in 2013 and is based in Irvine, California. |
Buy | - |
Sequence Life Science provides contract manufacturing and working with OEMs to facilitate their production needs. Sequence LifeScience possesses cleanroom capabilities for full tissue operations such as manufacturing, sterilization, and distribution. Sequence Life Science is based in San Antonio, Texas.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2024 M&A | 1 of 1 |
